Endogenous 3,4-Dihydroxyphenylalanine and Dopaquinone Modifications on Protein Tyrosine

LINKS TO MITOCHONDRIALLY DERIVED OXIDATIVE STRESS VIA HYDROXYL RADICAL*

Xu Zhang‡, Matthew E. Monroe‡, Baowei Chen‡, Mark H. Chin§, Tyler H. Heibeck‡, Athena A. Schepmoes‡, Feng Yang‡, Brianne O. Petritis‡, David G. Camp II‡, Joel G. Pounds‡, Jon M. Jacobs‡, Desmond J. Smith§, Diana J. Bigelow‡, Richard D. Smith‡, and Wei-Jun Qian‡¶

Oxidative modifications of protein tyrosines have been implicated in multiple human diseases. Among these modifications, elevations in levels of 3,4-dihydroxyphenylalanine (DOPA), a major product of hydroxyl radical addition to tyrosine, has been observed in a number of pathologies. Here we report the first proteome survey of endogenous site-specific modifications, i.e. DOPA and its further oxidation product dopaquinone in mouse brain and heart tissues. Results from LC-MS/MS analyses included 50 and 14 DOPA-modified tyrosine sites identified from brain and heart, respectively, whereas only a few nitrotyrosine-containing peptides, a more commonly studied marker of oxidative stress, were detectable, suggesting the much higher abundance for DOPA modification as compared with tyrosine nitration. Moreover, 20 and 12 dopaquinone-modified peptides were observed from brain and heart, respectively; nearly one-fourth of these peptides were also observed with DOPA modification on the same sites. For both tissues, these modifications are preferentially found in mitochondrial proteins with metal binding properties, consistent with metal-catalyzed hydroxyl radical formation from mitochondrial superoxide and hydrogen peroxide. These modifications also link to a number of mitochondrially associated and other signaling pathways. Furthermore, many of the modification sites were common sites of previously reported tyrosine phosphorylation, suggesting potential disruption of signaling pathways. Collectively, the results suggest that these modifications are linked with mitochondrially derived oxidative stress and may serve as sensitive markers for disease pathologies. Molecular & Cellular Proteomics 9:1199–1208, 2010.

From the ‡Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington 99352 and §Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095

Received, July 16, 2009, and in revised form, January 26, 2010

Published, MCP Papers in Press, February 2, 2010, DOI 10.1074/mcp.M900321-MCP200

This paper is available on line at http://www.mcponline.org

1 The abbreviations used are: ROS, reactive oxygen species; DOPA, 3,4-dihydroxyphenylalanine; DQ, dopaquinone; HO·, hydroxyl radical; FPR, false positive rate; PD, Parkinson disease; SCX, strong cation exchange; IPI, International Protein Index.
DOPA and Dopaquinone Modifications on Protein Tyrosine

![Chemical structure of DOPA and Dopaquinone modifications on protein tyrosine]

the chance of incorrect peptide assignments (19, 23). With recent advances in high resolution MS that provide high mass measurement accuracy, the ability to confidently identify modified peptides has been significantly enhanced (24).

Hydroxyl radical (HO·) is one of the most reactive and major species generated under aerobic conditions in biological systems (1, 25, 26). Among several HO·-mediated oxidative modifications, the protein tyrosine modification 3,4-dihydroxyphenylalanine (DOPA) has been reported as a major product and index of HO· attack on tyrosine residues in proteins (Fig. 1) (27, 28). DOPA is also formed on protein tyrosine residues via controlled enzymatic pathways through enzymes such as tyrosinase or tyrosine hydroxylase (28). Once formed, protein-bound DOPA has the potential to initiate further oxidative reactions through binding and reducing transition metals or through redox cycling between catechol and quinone (dopaquinone) forms (29, 30). Recent studies have suggested that protein-bound DOPA is involved in triggering antioxidant defenses (30) and mediating oxidative damage to DNA (31). Moreover, elevated levels of protein-bound DOPA have been reported in several diseases, including atherosclerosis, cancer, and myocardial disease, and in PD patients undergoing levodopa therapy (26, 32–36). However, the specific DOPA-modified proteins, which could provide mechanistic knowledge of the progression of these diseases, have not been identified (27, 28). The ability to identify site-specific protein modifications should lead to a better understanding of the role of DOPA modification in disease pathologies as well as new molecular signatures or therapeutic targets for diseases.

Therefore, in this study, we demonstrate the ability to identify site-specific DOPA and dopaquinone (DQ) modifications on protein tyrosine residues in normal mouse brain and heart tissues and their relative stoichiometries that are present in vivo under non-stressed conditions. Such endogenous protein modifications were detected using LC-MS/MS. The results from this global proteomics survey suggests that HO· in tissues under normal conditions is generated largely from the mitochondria and metal-binding proteins where the resulting DOPA/DQ modifications have the potential to disrupt mitochondrial respiration as well as alter tyrosine phosphorylation signaling pathways such as 14-3-3-mediated signaling in brain tissue.

EXPERIMENTAL PROCEDURES

Mouse Brain and Heart Tissue Sample Processing—Brain tissue was dissected from C57BL/6J male mice (8 weeks of age, 21–27 g) obtained from The Jackson Laboratory (Bar Harbor, ME) and frozen immediately in liquid nitrogen until use. Brain tissues from four mice were homogenized in 50 mM NH4HCO3 (pH 7.8), and protein concentrations were determined by the BCA assay (Pierce). All animal procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Heart tissue from 4-month-old female BALB/cByJNiaHsd mice was obtained from NIA, National Institutes of Health where tissues were frozen in liquid nitrogen after sacrifice and removal. All procedures were done on ice if not stated otherwise. Five frozen mouse hearts (1.2 g total) from five individual mice were pulverized with a mortar and pestle on dry ice followed by homogenization in 6–8 ml of 50 mM NH4HCO3 (pH 7.8), 150 mM NaCl with a Silverson L4R homogenizer (East Longmeadow, MA). Homogenates were centrifuged for 10 min at 500 × gmax and supernatants were filtered through one layer of cheesecloth into a clean precooled centrifuge tube. The resulting supernatants (soluble fractions) were saved.

Pooled brain and heart tissue homogenates with 300 μg of protein each were treated with 50% (v/v) trifluoroethanol (Sigma) for 2 h at 60 °C and then with 2 mM DTT (Sigma) for 1 h at 37 °C with gentle shaking at 300 rpm. Both samples were then diluted 5-fold with 50 mM NH4HCO3 and digested with sequencing grade trypsin to protein ratio (w/w). 1 mM CaCl2 was applied during the digestion. Peptides were recovered using solid phase extraction C18 column (Supelco, Bellefonte, PA) cleanup, dried down with a speed vacuum concentrator dissolved in 25 mM NH4HCO3, and stored at −80 °C until time for further analysis.

In Vitro Oxidation of Heart Peptide Sample—Mouse heart peptides were resuspended in 25 mM NH4HCO3 (pH 7.2) and incubated with the iron/EDTA/ascorbate system, which consisted of 50 mM sodium phosphate buffer (pH 7.2) containing 240 μM EDTA and 1 mM ascorbic acid (Sigma). The reaction was initiated by the addition of Fe2+ (FeSO4·7H2O) to a final concentration of 200 μM in a final volume of 100 μl. The sample was then incubated at room temperature for 1 h with constant shaking at 600 rpm. The incubation tube was opened and covered with Breathe-EASIER tube membrane (Diversified Biotech, Boston, Massachusetts) during the incubation to improve oxygenation. Control samples were treated without iron, EDTA, and ascorbate. Following the reaction, peptides were recovered by solid phase extraction C18 column (Supelco) cleanup, dried down in a speed vacuum concentrator dissolved in 25 mM NH4HCO3, and stored at −80 °C for further MS analysis.

Strong Cation Exchange (SCX) Fractionation—The dried peptides from mouse brain and heart were dissolved in 25 mM NH4HCO3 and subjected to HPLC (Agilent, Palo Alto, CA)-based SCX fractionation on a 200 × 2.1-mm (5-μm particles, 300-Å pore size) Polysofoethyl A column (PolyLC, Columbia, MD) at a flow rate of 0.2 ml/min. Mobile phase solvents consisted of 10 mM ammonium formate, 25% acetonitrile (pH 3.0) (A) and 500 mM ammonium formate, 25% acetonitrile (pH 6.8) (B). Once the column was loaded, isocratic conditions at 100% A were maintained for 10 min. Peptides were separated by using a gradient from 0 to 50% B over 40 min followed by a gradient of 50–100% B over 10 min. The gradient was then held at 100% solvent B for another 10 min. 30 fractions were collected for the heart sample, whereas 15 fractions were collected for the heart sample. Following lyophilization, the fractions were dissolved in 25 mM NH4HCO3 and stored at −80 °C until further use.

Nano-LC-MS/MS Analysis—All SCX fractions of mouse brain and heart samples as well as the in vitro oxidized heart sample were further analyzed using a fully automated custom-built four-column nano-HPLC system (37) coupled on line with an LTQ Orbitrap mass spectrometer (ThermoFinnigan, San Jose, CA) modified with an in-house manufactured electrospray ionization interface. The reversed phase capillary column was slurry-packed using 3-μm Jupiter C18.
DOPA and Dopaquinone Modifications on Protein Tyrosine

RESULTS

Endogenous DOPA- and DQ-modified Peptide Identifications from Mouse Brain and Heart Tissues—For the identification of DOPA- and DQ-modified proteins in heart and brain, we utilized a global profiling strategy, i.e. SCX fractionation coupled off line with reversed phase LC-MS/MS with high resolution parent mass measurements, which permits confident identification of several types of modified peptides and their native analogues in a complex mixture by applying a 5-ppm mass measurement accuracy constraint for the parent masses. Tryptic peptides from mouse brain or heart homogenates were fractionated by SCX, and the resulting peptide fractions were individually analyzed by high resolution nano-LC-MS/MS. Peptides were identified from MS/MS spectra by database searching using the X!Tandem algorithm (38). To identify the modified peptides, we included variable modifications on tyrosine residues with additional masses of 44.985, 15.995, and 13.979 Da, corresponding to nitrotyrosine, DOPA, and DQ modifications, respectively. Variable oxidative modifications (15.995 Da) on methionine, proline, and tryptophan were also included because these residues are also prone to oxidation (41). The inclusion of both DOPA- and nitrotyrosine-related modifications allows us to compare the relative prevalence between DOPA modification and nitration on protein tyrosine. The samples were analyzed on an LTQ Orbitrap mass spectrometer; the achievable ppm level mass accuracy on parent mass measurements allows us to achieve high confidence identifications and to differentiate the exact forms of DOPA and DQ modifications. One of the challenges in identifying low abundance modified peptides is the potential of false positive identifications. High FPR is often encountered if only a small number of modified peptides are identified among a large number of total peptide identifications. Following the application of 5-ppm mass tolerance and peptide expectation value cutoffs, we achieved <1% FPR for total peptide identifications in both tissues and a 1–5% FPR for DOPA- and DQ-modified peptide identifications based on decoy searching results; however, for nitrotyrosine-modified peptides, we observed ~ 40% FPR following the application of the same criteria due to the identification of significantly fewer nitrotyrosine peptides. Upon applying a more stringent filtering criteria requiring peptide expectation values (log(e)) of <-2 and <-3 for fully or partially tryptic peptides and further manual spectrum examination, we only identified two nitrotyrosine sites from the brain tissue (Table I).

Table I lists the total number of peptides and proteins from global profiling of both tissues and the number of reverse hits as well as the number of unique modified peptides identified for each type of modification before and after manual inspection from mouse brain and heart tissues. The potential of oxidative modifications on multiple amino acid residues including methionine, proline, tryptophan, and tyrosine often...
makes it a challenge to determine the exact modification site for a given peptide even if the peptide sequence along with the modification mass is correctly identified. In the manual inspection process, only those peptides with unambiguous site identifications were retained as final identified DOPA- and DQ-modified peptides as listed in supplemental Tables 1 and 2. For the global profiling, we identified 26,572 peptides and 4,656 proteins from brain and 9,409 peptides and 1,914 proteins from heart. A total of 63 unique modified tyrosine sites was identified in the mouse brain, corresponding to 53 proteins; 50 and 20 of these sites were modified with DOPA and DQ, respectively. For mouse heart, a total of 23 unique modified tyrosine sites was identified, corresponding to 19 proteins; 14 and 12 of these sites were modified with DOPA and DQ, respectively. Thus, the percentage of DOPA/DQ-modified peptides relative to the total number of identified peptides is similar for both tissues, i.e. \( \approx 0.24\% \). The relative stoichiometry of modified tyrosine sites was approximated by comparing spectral count (the number of MS/MS spectra resulting in the identification of a given peptide) information for modified and unmodified versions of each peptide; the majority of tyrosine sites were observed with a stoichiometry of less than 10%. Moreover, only one or two tyrosine modification sites were observed per protein as expected for endogenous modifications in normal tissues. When data sets for mouse brain and heart were combined, 81 unique tyrosine sites modified from 67 proteins were observed of a total 880 tyrosine sites from these proteins (supplemental Tables 4 and 5). It is interesting to note that we only identified two nitrotyrosine sites from the same brain tissue. The results again illustrate the challenge for effectively identifying tyrosine nitration using global proteome analyses without enrichment, presumably due to the low abundance of endogenous protein tyrosine nitration. This observation is in good agreement with our previous effort for nitrotyrosine profiling where the majority of nitrotyrosine-containing peptides were identified from a cysteinyl peptide-enriched sample from mouse brain (19). On the other hand, DOPA and DQ modifications on tyrosine are more readily detectable and should be more feasible for exploring the role of these modifications as potential biomarkers for oxidative stress and inflammation.

Fig. 2 shows an example MS/MS spectra of one peptide, VWAGVATALAHKYH, from the hemoglobin \( \beta \) subunit in both its unmodified and DOPA- and DQ-modified versions. Note that the \( b \) and \( y \) fragment ions for the three versions of this peptide match with the exception of \( b \) and \( y \) ions that contain modified tyrosine residues, i.e. \( b_{13} \) and \( y_{2–12} \), where DOPA- or DQ-modified peptides have masses that are 15.99 or 13.98 Da, respectively, higher than those of the corresponding ions from the non-modified peptide.

**Enhanced DOPA Modification following in Vitro HO\(^{–}\) Exposure**—Because DOPA has been suggested to be the major product of HO\(^{–}\) attack on tyrosine residues (27, 42), we applied an *in vitro* exposure to HO\(^{–}\) using iron/EDTA/ascorbate to generate HO\(^{–}\) (28). About twice as many unique modified peptides (seven DOPA- and six DQ-modified peptides) were identified from single dimensional LC-MS/MS analyses of the iron/EDTA/ascorbate-treated heart sample as compared with the number of unique peptides (two DOPA- and four DQ-modified peptides) identified in the control. In addition, the spectral count of many modified peptides also increased following the chemical treatment, again reflecting enhanced tyrosine hydroxylation. Fig. 3 shows the total spectral count comparison of selected proteins before and after *in vitro* hydroxylation treatment where the results clearly illustrate the increased extent of modifications following the chemical treatment. A detailed report of this result is available as supplemental Table 3. Thus, these *in vitro* results suggest that endogenous DOPA and DQ modifications reflect the *in vivo* formation of HO\(^{–}\).

**Preferential DOPA/DQ Modification of Mitochondrial Proteins**—To examine what types of proteins are more sensitive to HO\(^{–}\) attack, we categorized the cellular localization of modified proteins from mouse brain and heart based on their gene ontology annotations. Fig. 4 shows that \( \approx 44\% \) of modified proteins were localized in the mitochondria for both tissues. These values are nearly twice the percentage of the unmodified mitochondrial proteins identified in these global profiling data, showing a clear preference for DOPA/DQ modification of mitochondrial proteins, in good agreement with the pivotal role of mitochondria in generating ROS (43).

Fig. 5 shows the top pathways represented by DOPA- and DQ-modified proteins from mouse brain and heart tissues.
based on analysis using the Ingenuity Pathways Analysis tool (44). Consistent with the large percentage of modified proteins in mitochondria (Fig. 4), several mitochondrially associated pathways, including oxidative phosphorylation, citrate cycle, and mitochondrial dysfunction, were observed to be significant. For example, malate dehydrogenase 2 (Mdh2), a key enzyme in the citrate cycle, was modified in brain tissue. Multiple ATP synthases (Atp5b, Atp5o, Atp5h, Atp6v0d1, and Atp6v0a1) and ubiquinol-cytochrome c (Uqcrb) involved in the oxidative phosphorylation pathway were also modified.

In addition to mitochondrion-related pathways, several other signaling pathways were observed with significance, for example the nuclear factor-like 2 (Nrf2)-mediated oxidative stress response pathway in heart tissue. For this pathway, modifications occur on both cytoskeletal proteins (e.g., actin β, α, and γ1) and cytosolic enzymes (e.g., 90-kDa heat shock proteins (Hsp90aa1 and Hsp90ab1)). Interestingly, 14-3-3-
mediated signaling and phosphatidylinositol 3-kinase/AKT signaling pathways were only observed with significance in mouse brain tissue. A significant contribution to these pathways is the modifications observed on several members of the 14-3-3 protein complex (Table II). The 14-3-3 proteins are known to be abundantly expressed in the brain and play important function in the nervous system (45). The observed modifications on multiple isoforms of α- and β-tubulin associated with the 14-3-3-mediated signaling are also interesting because the role of 14-3-3 proteins in cytoskeletal regulation has been reported (46).

Of particular interest was the identification of a number of known tyrosine phosphorylation sites that were modified by DOPA and DQ, suggesting that 3-hydroxylation of tyrosine represents a new mechanism for disrupting cell signaling regulated by tyrosine phosphorylation. By mapping the identified DOPA-modified tyrosine sites to the Phosphosite database, we observed 21 and three unique tyrosine sites corresponding to 19 and three proteins, respectively (see supplemental Tables 1 and 2). Among these, three of seven...
modification sites observed in 14-3-3 proteins comprise known tyrosine phosphorylation sites (Table II). We also note that the numbers of mapped known phosphorylated sites are limited by the current available database for which new sites are continually being added.

**DISCUSSION**

As oxidative stress has been recognized as central to many pathologies, so have oxidative modifications of proteins been implicated in the pathogenesis of multiple human diseases (22). Of particular interest are oxidative modifications on protein tyrosines because of their potential role in disrupting catalysis, protein-protein interactions, and cell signaling mediated by tyrosine phosphorylation. To date, most studies have been focused on the characterization of tyrosine nitration where elevated levels of nitrotyrosine have been observed in multiple inflammatory diseases (2, 47). Similarly, increases in total protein DOPA levels have been linked with several diseases (3), whereas the relative percentage of DOPA/DQ-modified peptides in brain, where tyrosinase and tyrosine hydroxylase are more highly expressed, was not greater than that in the heart (Table I). The observed preferential modification of mitochondrial proteins by DOPA/DQ further suggests their origins from short lived and/or non-diffusive ROS generated in mitochondria. These criteria are fulfilled by the mitochondrial generation of superoxide anion ($\text{O}_2^-$), which can be readily converted to the oxidant $\text{H}_2\text{O}_2$ by superoxide dismutase followed by its further reaction to $\text{HO}^+$ by Fenton chemistry in the presence of transition metals. Neither superoxide nor $\text{HO}^+$ is highly diffusive; in particular, the high reactivity of $\text{HO}^+$ means that it diffuses only the diameter of a typical protein within its lifetime (2). Mitochondria are noted as the repositories of cellular pools of iron, copper, manganese, and zinc, all required as cofactors for mitochondrial respiration. In particular, in the case of copper, $\sim$80% of this metal is not bound to proteins but localized within the mitochondrial matrix as a soluble ligand complex (48, 49). Thus, the high levels of both protein-bound and exchangeable metals within mitochondria could provide a source of potential Fenton chemistry to produce $\text{HO}^+$. Indeed, in our proteomics analysis, a substantial amount of mitochondrial metalloproteins was observed to be modified by DOPA/DQ (50). Some examples are the cytochrome c (Cycl), cytochrome bc$_1$ complex (Uqcrb), and the ATP synthases (Atp5h, Atp5b, and Atp5o). We also note that multiple isoforms of hemoglobin, an extracellular metalloprotein, incorporated significant levels of DOPA/DQ modifications. Additionally, the mitochondrially expressed antioxidant enzyme manganese-superoxide dismutase (Sod2) was found to be modified at Tyr-34 (within the peptide HHAAY*VNN) in both brain and heart; nitration of this same site has been demonstrated to inhibit enzyme activity (2).

Besides mitochondrial proteins, we observed modifications on many cytoskeletal proteins, reflecting known metal binding properties of cytoskeletal proteins, such as actin and tubulin, as well as the proximity of the cytoskeleton to mitochondria in both brain and heart (51). In mouse brain, DOPA/DQ modifications were also observed on several members of the 14-3-3 protein complex, a class of proteins also reported to have metal ion binding properties (52); however, there is a potential...
role of tyrosine hydroxylase for these modifications because the 14-3-3 proteins are known to interact with proteins that display tyrosine hydroxylase activity. Given the importance of metal-binding proteins in protein structural stability, cell signaling, regulation, transport, immune response, metabolism control, and metal homeostasis, selective DOPA modification on tyrosine sites in these proteins should play a significant role in cellular functions.

As the major source of cellular ROS, mitochondria are not only sensitive to oxidative damage but also play a crucial role in disease pathogenesis because mitochondrial dysfunction and oxidative stress are recognized as important contributing factors in the development of neurodegenerative, cardiovascular, and aging-related diseases (43, 53–55). The high percentage of identified modified proteins localized in mitochondria suggests that DOPA modification may represent a significant mechanism contributing to mitochondrial dysfunction as evidenced by several mitochondrial-related pathways that appear significantly affected by these modifications, e.g., mitochondrial dysfunction and oxidative phosphorylation. Elevated levels of HO− were also observed in the striatum and ventral midbrain regions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice (56), a commonly used model for PD, supporting that many mitochondrial proteins may have an elevated level of DOPA/DQ as induced by an increased level of HO−.

A number of cytosolic oxidative stress response proteins, such as 90-kDa heat shock proteins and 14-3-3 signaling proteins, appeared susceptible to modifications. 90-kDa heat shock proteins (HSP90) are essential chaperones (stress proteins) for promoting cell survival under oxidative stress conditions and targets for halting neurodegeneration (57). Moreover, all five observed tyrosine sites in HSP90 that were modified by DOPA/DQ are reported to be sites of phosphorylation. The observation of DOPA/DQ modifications on three members of the 14-3-3 protein complex (Table II) is of particularly interest because these proteins are known to have important roles in the nervous system by interacting with more than 100 binding partners and have been implicated in many neurological disorders (45). These proteins are also known as tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation proteins that bind and regulate tyrosine hydroxylase (58), which mediates the rate-limiting step of dopamine and neurotransmitter synthesis in the brain. The observed modifications on multiple isoforms of α- and β-tubulin associated with 14-3-3-mediated signaling are also of interest because of the role of 14-3-3 proteins in cytoskeletal regulation (46). Again, nearly half of the DOPA-modified tyrosine sites are reported phosphorylation sites (Table II).

The modifications observed on a number of cytoskeletal proteins may also have implications in disease because cytoskeleton integrity is essential for normal cell functions; abnormalities in cytoskeleton organization have been observed in many diseases, especially neurodegenerative diseases (59). In particular, actin is sensitive to oxidant attack and is a key regulator of apoptosis and aging (60, 61). DOPA modifications were observed in multiple isoforms of actin and tubulin. Several actin and tubulin proteins were also observed with tyrosine nitration in our previous study of mouse brain (19). Because many of the identified DOPA modification sites in these single proteins are the same sites reported to be phosphorylated or nitrated, tyrosine DOPA modification and nitration may represent two mechanisms for disrupting oxidative stress response signaling, 14-3-3 signaling, and cytoskeletal organization in disease pathogenesis by either disrupting tyrosine phosphorylation signaling or diminishing enzymatic activities. The much higher abundance of observed DOPA modifications compared with nitrotyrosine suggests that DOPA modification represents a better marker for mitochondrial dysfunction and oxidative stress than nitrotyrosine; however, nitrotyrosine should still be a complementary marker to DOPA because nitrotyrosine is an inflammation-specific marker for nitric oxide-derived oxidation (19).

In summary, the observation of prevalent DOPA and DQ modifications on protein tyrosine, their preferential localization in mitochondria, their selectivity for metal-binding proteins, the associations with important cell signaling pathways, and their potential implications in diseases suggest that these modifications are linked to mitochondrial dysfunction and oxidative stress. Moreover, the fact that the sites of DOPA modifications are frequently reported as sites of tyrosine phosphorylation and nitration further supports these modifications as significant in disrupting cell signaling. DOPA/DQ tyrosine modifications are also complementary to those of nitrotyrosine because DOPA/DQ constitute a marker of HO− chemistries in contrast to nitrotyrosine, which reflects the presence of reaction nitrogen species, thus distinguishing inflammatory from non-inflammatory physiological states.

**Acknowledgments**—The experimental work was performed in the Environmental Molecular Sciences Laboratory, a United States Department of Energy (DOE) Office of Biological and Environmental Research national scientific user facility on the Pacific Northwest National Laboratory (PNNL) campus. PNNL is a multiprogram national laboratory operated by Battelle for the DOE under Contract DE-AC05-76RLO 1830.

* This work was supported, in whole or in part, by National Institutes of Health Grant ES016015 from the Center for Novel Biomarkers of Response (to J. G. P.), Grant RR018522 from the Center of Proteomics Research Resource for Integrative Biology (to R. D. S.), Grant R01 NS050148 (to D. J. S.), and Grant R01 DK074795 (to R. D. S.). This work was also supported by the Pacific Northwest National Laboratory Directed Research Development Program (to W.-J. Q.).

† To whom correspondence should be addressed: Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, P. O. Box 999, Richland, WA 99352. Tel.: 509-371-6572; Fax: 509-371-6546; E-mail: weijun.qian@pnl.gov.
REFERENCES

1. Berlett, B. S., and Stadtman, E. R. (1997) Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272, 20315–20316
2. Pacher, P., Beckman, J. S., and Lu, A. (2007) Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315–424
3. Benz, C. C., and Yau, C. (2008) Ageing, oxidative stress and cancer: paradigms in parallax. Nat. Rev. Cancer 8, 875–879
4. Stadtman, E. R. (1992) Protein oxidation and aging. Science 257, 1220–1224
5. Danielson, S. R., and Andersen, J. K. (2008) Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radic. Biol. Med. 44, 1787–1794
6. Grimsrud, P. A., Xie, H., Griffin, T. J., and Bernlohr, D. A. (2008) Oxidative stress and covalent modification of protein with bioactive aldehydes. J. Biol. Chem. 283, 21837–21841
7. Derakhshan, B., Wille, P. C., and Gross, S. S. (2007) Unbiased identification of autophosphorylation sites on proteins. Nat. Protoc. 2, 1685–1691
8. Hao, G., Derakhshan, B., Shi, L., Campagne, F., and Gross, S. S. (2006) SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. Proc. Natl. Acad. Sci. U.S.A. 103, 1012–1017
9. Torta, F., Usuelli, V., Malgaroli, A., and Bachi, A. (2008) Proteomic analysis of protein S-nitrosylation. Proteomics 8, 4484–4494
10. Peterson, J. J., Kula, A., Ambrosio, C., Scaloni, A., D’Auria, F., Prescott, A., Domante, G., and Tell, G. (2004) A proteomic approach to identify early molecular targets of oxidative stress in human epithelial lens cells. Biochem. J. 376, 929–937
11. Rabilloud, T., Keller, M., Gasnier, F., Luche, S., Rey, C., Aebersold, R., Colombo, R., Rossi, R., and Milzani, A. (2005) Proteins as biomarkers of oxidative stress in acute liver failure. J. Proteome Res. 4, 55–99
12. Stevens, S. M., Jr., Prokai-Tatrai, K., and Prokai, L. (2008) Factors that contribute to the misidentification of tyrosine nitration by shotgun proteomics. Mol. Cell. Proteomics 7, 2442–2451
13. Haas, W., Faherty, B. K., Gerber, S. A., Elias, J. E., Beausoleil, S. A., Bakalarski, C. E., Li, X., Villen, J., and Gyg, S. P. (2006) Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol. Cell. Proteomics 5, 1327–1337
14. Garrison, W. M. (1987) Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 87, 381–398
15. Dean, R. T., Fu, S., Stocker, R., and Davies, M. J. (1997) Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 324, 1–18
16. Gieseg, S. P., Simpson, J. A., Chalton, T. S., Duncan, M. W., and Dean, R. T. (1993) Protein-bound 3,4-dihydroxyphenylalanine is a major reductant oxidized during hydroxyl radical damage to proteins. Biochemistry 32, 4780–4786
17. Cohen, G., Yakuskin, S., and Dembic-Cohen, D. (1998) Protein L-dopa as an index of hydroxyl radical attack on protein tyrosine. Anal. Biochem. 263, 232–239
18. Rodgers, K. J., and Dean, R. T. (2000) Metabolism of protein-bound DOPA in mammals. Int. J. Biochem. Cell Biol. 32, 945–955
19. Nelson, M., Foxwell, A. R., Tyner, R., and Dean, R. T. (2007) Protein-bound 3,4-dihydroxy-phenylalanine (DOPA), a re-oxidative product of protein oxidation, as a trigger for antioxidant defences. Int. J. Biochem. Cell Biol. 39, 879–889
20. Morin, B., Davies, M. J., and Dean, R. T. (1998) The protein oxidation product 3,4-dihydroxyphenylalanine (DOPA) mediates oxidative DNA damage. Biochem. J. 330, 1059–1067
21. Fu, S., Davies, M. J., Stocker, R., and Dean, R. T. (1998) Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochim. Biophys. Acta 1331, 519–525
22. Fu, S., Dean, R., Southan, M., and Truscott, R. (1998) The hydroxyl radical in lens nuclear cataractogenesis. J. Biol. Chem. 273, 28603–28609
23. Wood, A. A., Linton, S. M., and Davies, M. J. (2003) Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem. J. 370, 729–735
24. Morin, B., Davies, M. J., and Dean, R. T. (2003) Probability of protein-bound DOPA in cataractous lenses is accompanied by a lower protein and phenylalanine content of the water-soluble phase. Free Radic. Biol. Med. 39, 1359–1366
25. O’Neill, C. A., Fu, L. W., Halliwell, B., and Longhurst, J. C. (1996) Hydroxyl radical production during myocardial ischemia and reperfusion in cats. Ann. N.Y. Acad. Sci. 1034, 284–289
26. Cullingsford, T. E., Wat, R., Clerk, A., and Sugden, P. H. (2006) Effects of oxidative stress on the cardiac myocyte proteome: modifications to peroxiredoxins and small heat shock proteins. J. Mol. Cell. Cardiol. 40, 157–172
27. Aulak, K. S., Miyagi, M., Yan, L., West, K. A., Massillon, D., Crabb, J. W., and Stuehr, D. J. (2001) Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc. Natl. Acad. Sci. U.S.A. 98, 12056–12061
28. Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., Markesbery, W. R., and Butterfield, D. A. (2003) Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J. Neurochem. 85, 1394–1401
29. Kanski, J., Hong, S. J., and Schloenich, C. (2005) Proteomic analysis of protein nitration aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J. Biol. Chem. 280, 24561–24566
30. But, Y. K., and Lo, S. C. (2008) Detecting nitrated proteins by proteomic technologies. Methods Enzymol. 440, 17–31
31. Sackstedter, C. A., Qian, W. J., Knyshtso, T. V., Wang, H., Chin, M. H., Lacan, G., Melega, W. P., Camp, D. G., 2nd, Smith, R. D., Smith, D. J., Squier, T. C., and Bigelow, D. J. (2008) Endogenously nitrated proteins in mouse brain: links to neurodegenerative disease. Biochemistry 45, 8009–8022
32. Bigelow, D. J., and Qian, W. J. (2008) Quantitative proteomic mapping of nitrotyrosines. Methods Enzymol. 440, 191–205
33. Zhang, Q., Qian, W. J., Knyshtso, T. V., Clauss, T. R., Purvine, S. O., Moore, R. J., Sackstede, C. A., Chin, M. H., Smith, D. J., Camp, D. G., 2nd, Bigelow, D. J., and Smith, R. D. (2007) A method for selective enrichment and analysis of nitrotyrosine-containing peptides in complex proteome samples. J. Proteome Res. 6, 2257–2268
34. Dalle-Donne, I., Scaloni, A., Giustarini, D., Cavarra, E., Tell, G., Lungarella, G., Colombo, R., Rossi, R., and Milzani, A. (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom. Rev. 24, 55–99
35. Calvano, S. E., Xiao, W., Richards, D. R., Felciano, R. M., Baker, H. V., Cho, R. J., Chen, R. O., Brownstein, B. H., Cobb, J. P., Tschoeke, S. K., Miller-Graziano, C., Moldawer, L. L., Mindrinos, M. N., Davis, R. W., and Butterfield, D. A. (2003) Proteomic identification of nitrated proteins in atherosclerotic plaques. J. Mol. Cell. Cardiol. 35, 2328–2335
36. Bakalarski, C. E., Li, X., Ville´ n, J., and Gygi, S. P. (2006) Optimization and general scoring schemes. Mol. Cell. Proteomics 5, 1327–1337
37. Lin, M. T., and Beal, M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795
38. DOPA and Dopaquinone Modifications on Protein Tyrosine
Tompkins, R. G., and Lowry, S. F. (2005) A network-based analysis of systemic inflammation in humans. Nature 437, 1032–1037
45. Berg, D., Holzmann, C., and Riess, O. (2003) 14-3-3 proteins in the nervous system. Nat. Rev. Neurosci. 4, 752–762
46. Jin, J., Smith, F. D., Stark, C., Wells, C. D., Fawcett, J. P., Kulkarni, S., Metalnikov, P., O’Donnell, P., Taylor, P., Taylor, L., Zougman, A., Woodgett, J. R., Langeberg, L. K., Scott, J. D., and Pawson, T. (2004) Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr. Biol. 14, 1436–1450
47. Yeo, W. S., Lee, S. J., Lee, J. R., and Kim, K. P. (2008) Nitrosative protein tyrosine modifications: biochemistry and functional significance. BMB Rep. 41, 194–203
48. Leary, S. C., Winge, D. R., and Cobine, P. A. (2009) “Pulling the plug” on cellular copper: the role of mitochondria in copper export. Biochim. Biophys. Acta 1793, 146–153
49. Pierrel, F., Cobine, P. A., and Winge, D. R. (2007) Metal ion availability in mitochondria. Biometals 20, 675–682
50. Hosler, J. P., Ferguson-Miller, S., and Mills, D. A. (2006) Energy transduction: proton transfer through the respiratory complexes. Annu. Rev. Biochem. 75, 165–187
51. Hedberg, K. K., Birrell, G. B., and Griffith, O. H. (1991) Phorbol ester-induced actin cytoskeletal reorganization requires a heavy metal ion. Cell Regul. 2, 1067–1079
52. Athwal, G. S., Huber, J. L., and Huber, S. C. (1998) Biological significance of divalent metal ion binding to 14-3-3 proteins in relationship to nitrate reductase inactivation. Plant Cell Physiol. 39, 1065–1072
53. Molavi, B., and Mehta, J. L. (2004) Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr. Opin. Cardiol. 19, 488–493
54. Andersen, J. K. (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med. 10, (suppl.) S18–S25
55. Ballinger, S. W. (2005) Mitochondrial dysfunction in cardiovascular disease. Free Radic. Biol. Med. 38, 1278–1295
56. Smith, T. S., and Bennett, J. P., Jr. (1997) Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions. Brain Res. 765, 183–188
57. Gallo, K. A. (2006) Targeting HSP90 to halt neurodegeneration. Chem. Biol. 13, 115–116
58. Obsilova, V., Nedbalkova, E., Silhan, J., Boura, E., Herman, P., Vecer, J., Sulc, M., Teisinger, J., Dyda, F., and Obsil, T. (2008) The 14-3-3 protein affects the conformation of the regulatory domain of human tyrosine hydroxylase. Biochemistry 47, 1768–1777
59. Brandt, R. (2001) Cytoskeletal mechanisms of neuronal degeneration. Cell Tissue Res. 305, 255–265
60. Dalle-Donne, I., Rossi, R., Milzani, A., Di Simplicio, P., and Colombo, R. (2001) The actin cytoskeleton response to oxidants: from small heat shock protein phosphorylation to changes in the redox state of actin itself. Free Radic. Biol. Med. 31, 1624–1632
61. Gourlay, C. W., and Ayscough, K. R. (2005) The actin cytoskeleton in ageing and apoptosis. FEBS Yeast Res. 5, 1193–1198